This imminent licensing deal, may be laying the foundation for the structure of a future licensing model agreement for Pluristem and Big Pharma?
Protalix Biotherapeutics Inc. (AMEX:PLX; TASE: PLX) is close to signing an agreement for selling its Gaucher's disease treatment to the government of Brazil, in a deal worth hundreds of millions of dollars. Sources close to the deal told "Globes" that it would probably be signed within a few days.
Protalix is negotiating with the Brazilian government together with pharmaceutical giant Pfizer, which markets Protalix's drug exclusively throughout the world, apart from in Israel, where Protalix markets the drug itself.
Pfizer and Protalix will divide revenue from the drug, 60% to Pfizer and 40% to Protalix. Pfizer is responsible for marketing and marketing expenses, while Protalix is responsible for production and ancillary expenses. Protalix would not comment on the report.
Protalix shares are up about 0.5% on the Tel Aviv Stock Exchange today. The company has a market cap of about NIS 1.7 billion.
The current quarter is the first full quarter in which the drug is being sold. It received approval in May.
Published by Globes [online], Israel business news on November 13, 2012
Allo~ "This may become the lynchpin agreement that may and I say may, become the basis of future formal licensing agreements between Pluristem and Big Pharma in the near future for the myriad of indications that PLX Cells may treat? As this landmark licensing agreement may become the cornerstone for Pluristem and the industry? It is a very real possibility!
If one has learned anything in the past 1-2 weeks, never sell PSTI in a panic, unless you think Fisher Scientific is unable to maintain their cold storage facility in the United States into the future! Lesson Learned!